Show simple item record

dc.contributor.authorYin, Lina
dc.contributor.authorHu, Qingzhong
dc.contributor.authorHartmann, Rolf W
dc.date.accessioned2013-08-01T09:32:52Z
dc.date.available2013-08-01T09:32:52Z
dc.date.issued2013
dc.identifier.citationRecent progress in pharmaceutical therapies for castration-resistant prostate cancer. 2013, 14 (7):13958-78 Int J Mol Scien_GB
dc.identifier.issn1422-0067
dc.identifier.pmid23880851
dc.identifier.doi10.3390/ijms140713958
dc.identifier.urihttp://hdl.handle.net/10033/297195
dc.description.abstractSince 2010, six drugs have been approved for the treatment of castration-resistant prostate cancer, i.e., CYP17 inhibitor Abiraterone, androgen receptor antagonist Enzalutamide, cytotoxic agent Cabazitaxel, vaccine Sipuleucel-T, antibody Denosumab against receptor activator of nuclear factor kappa B ligand and radiopharmaceutical Alpharadin. All these drugs demonstrate improvement on overall survival, expect for Denosumab, which increases the bone mineral density of patients under androgen deprivation therapy and prolongs bone-metastasis-free survival. Besides further CYP17 inhibitors (Orteronel, Galeterone, VT-464 and CFG920), androgen receptor antagonists (ARN-509, ODM-201, AZD-3514 and EZN-4176) and vaccine Prostvac, more drug candidates with various mechanisms or new indications of launched drugs are currently under evaluation in different stages of clinical trials, including various kinase inhibitors and platinum complexes. Some novel strategies have also been proposed aimed at further potentiation of antitumor effects or reduction of side effects and complications related to treatments. Under these flourishing circumstances, more investigations should be performed on the optimal combination or the sequence of treatments needed to delay or reverse possible resistance and thus maximize the clinical benefits for the patients.
dc.language.isoenen
dc.rightsArchived with thanks to International journal of molecular sciencesen_GB
dc.titleRecent progress in pharmaceutical therapies for castration-resistant prostate cancer.en
dc.typeArticleen
dc.contributor.departmentPharmaceutical and Medicinal Chemistry, Saarland University & Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus C2-3, Saarbrücken D-66123, Germany. q.hu@mx.uni-saarland.de.en_GB
dc.identifier.journalInternational journal of molecular sciencesen_GB
refterms.dateFOA2018-06-13T15:16:32Z
html.description.abstractSince 2010, six drugs have been approved for the treatment of castration-resistant prostate cancer, i.e., CYP17 inhibitor Abiraterone, androgen receptor antagonist Enzalutamide, cytotoxic agent Cabazitaxel, vaccine Sipuleucel-T, antibody Denosumab against receptor activator of nuclear factor kappa B ligand and radiopharmaceutical Alpharadin. All these drugs demonstrate improvement on overall survival, expect for Denosumab, which increases the bone mineral density of patients under androgen deprivation therapy and prolongs bone-metastasis-free survival. Besides further CYP17 inhibitors (Orteronel, Galeterone, VT-464 and CFG920), androgen receptor antagonists (ARN-509, ODM-201, AZD-3514 and EZN-4176) and vaccine Prostvac, more drug candidates with various mechanisms or new indications of launched drugs are currently under evaluation in different stages of clinical trials, including various kinase inhibitors and platinum complexes. Some novel strategies have also been proposed aimed at further potentiation of antitumor effects or reduction of side effects and complications related to treatments. Under these flourishing circumstances, more investigations should be performed on the optimal combination or the sequence of treatments needed to delay or reverse possible resistance and thus maximize the clinical benefits for the patients.


Files in this item

Thumbnail
Name:
Yin et al_final.pdf
Size:
358.8Kb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record